Hypertension and Cardiovascular Risk Factors
Phase 4
Completed
- Conditions
- HYPERTENSION
- Registration Number
- NCT00171782
- Lead Sponsor
- Novartis
- Brief Summary
A study to evaluate the efficacy of valsartan+chydochlorothiazide in patients with stage 2 hypertension and cardiovascular risk factors.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 76
Inclusion Criteria
-
- Patients who give consent
- Men and women 18 to 80 years of age
- Patients with hypertension (systolic >159 mm, diastolic >100 mm)
- Patients meeting laboratory criteria
Exclusion Criteria
-
- Pregnant women
- Women not using approved contraception methods
- Secondary hypertension
Other protocol-defined exclusion criteria may apply.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Change from baseline systolic blood pressure at 8 weeks
- Secondary Outcome Measures
Name Time Method Reduction from baseline in systolic blood pressure greater than or equal to 20 mmHg Blood pressure less than 140/90 mmHg at 8 weeks Reduction from baseline in diastolic blood pressure greater than or equal to 10 mmHg